Background: Prostate cancer (PC) is a common noncutaneous malignancy in men. The incidence of PC is increasing at an alarming rate across the globe. Progression of PC is associated with elevated levels of interleukin-8 (IL-8) and cyclooxygenase-2 (COX-2) in malignant cells. Overexpression of these players is accompanied by chronic inflammation, increased angiogenesis, proliferation, migration, and inhibition of apoptosis. Moreover, their elevated circulating levels promote the disease progression from androgendependent to androgen-independent state. Thus, inhibiting the expression of IL-8 and COX-2 would be a promising target in the development of PC therapeutics. In this study, we investigated the inhibitory effects of Withania somnifera extract on highly metastatic, androgen-independent prostate cancer cell line (PC3). Additionally, we compared the real-time expression of IL-8 and COX-2 in prostate tissue samples. Materials and methods: The cell viability and cytotoxicity of W. somnifera extract in PC3 cells was quantified colorimetrically by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and lactate dehydrogenase leakage assay, respectively. Hematoxylin and eosin staining for histological examination, trypan blue, and acridine orange dyes to enumerate apoptotic and live cells, quantitative real-time polymerase chain reaction to determine the expression and flow cytometry to study the cell cycle analysis were used. Results: We observed a significant decrease in the cell viability with a half-maximal inhibitory concentration (IC 50 ) of 10 mg/mL. The expression levels of IL-8 and COX-2 in prostate tissue samples and in PC3 cells were predominantly high; however, the lowest dose of W. somnifera significantly inhibited the enhanced expression of IL-8 and COX-2 in PC3 cells in 24 hours. Furthermore, W. somnifera extract (10 mg/ mL) irreversibly arrested the cell cycle in G 2 /M phase, which was evident from the rapid accumulation of PC3 cells significantly. Conclusion: Our results indicate that inherent metastatic and selective inhibitory potential of W. somnifera against PC. W. somnifera may be a good therapeutic agent in addition to the existing drugs for PC. Further studies with more prostate tissue samples are warranted.
Introduction
Prostate cancer is one of the leading causes of death among all cancers in elderly men worldwide. 1, 2 Because of the growing and aging of the world's population, by 2030 the prostate cancer burden is expected to reach 1.7 million cases. 3 Progression of prostate cancer is orchestrated by various unusual physiological functions such as sustained cell proliferation, resisted cell death, increased cellular inflammation, excessive angiogenesis, and altered metastatic gene expression. 4 Importantly, modulation of androgen receptor signals mediates the prostatic tumorigenesis. 5 Surgery, hormonal therapy, radiotherapy, and chemotherapy are successful treatment strategies so far, but are limited based on patient's age, hormonal deprivation, sensitivity, and resistance to therapeutic drugs. 6, 7 In recent years, plant-derived extracts have drawn attention because of their richest bioactive compounds and their inherent ability to suppress the pathogenesis of cancers. Withania somnifera, one of the highly revered Indian herbs, possesses high medicinal value and has been traditionally used for the treatment of cancers, as well as inflammatory and neurological disorders. 8e13 Active principles of W. somnifera, which include alkaloids (anaferine), steroidal lactones (withanolides and withaferins), and saponins, are found to have anti-inflammatory activity in experimental animals. 11, 14 Extensive studies are carried out using the W. somnifera crude extracts and demonstrated its inherent adaptogenicity, antibacterial, and immunomodulatory potential. 15e17 It is effectively used in the prevention and treatment of stress-associated diseases such as arthritis, aging, arteriosclerosis, diabetes, hypertension, and malignancies. 12, 18 W. somnifera showed cytotoxic effects in many cancer cell lines including prostate cancer cells. The ethanolic extract of W. somnifera suppressed the lipopolysaccharide-induced production of inflammatory cytokines in peripheral blood mononuclear cells. 19 Suppression of angiogenesis and alteration of the cytoskeletal architecture have also been reported. 14, 20 Accumulated research reports, epidemiological studies, and surveys highlight the beneficial and therapeutic effects of W. somnifera extracts; however, research studies addressing the influence of W. somnifera extracts in androgen-dependent and androgen-independent prostate cancer treatment are needed to better understand the mode of disease progression. It was reported that the levels of IL-8, a multifunctional chemokine, and COX-2, a proinflammatory and proangiogenic enzyme, are significantly high in prostatic adenocarcinoma; it may also play a key role in the proliferation, invasion, and metastasis in prostate cancer cells. 21, 22 Hence, we investigated the effects of W. somnifera extract on proliferation, metastasis, and cell cycle transition in androgenindependent prostate cancer cells (PC3) through the expression of IL-8 and COX-2 in comparison with prostatic adenocarcinoma tissues. In addition, we examined the cell cycle checkpoint markers, cyclins A2, B1, and D1, using expression studies.
Materials and methods

Materials
Cryovials for tissue sample collection (Tarsons, Cat: 523040), reagents required for RNA isolation, namely, TRI reagent (Cat: T9424), Chloroform (Cat: V800116), isopropanol (Cat: V800228), formaldehyde (Cat: V800189), MOPS (Cat: M1254), DEPC (Cat: D5758) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reagent (Cat: M2128), were purchased from SigmaAldrich. Mayer's hematoxylin (Himedia Cat: S058) and eosin (Himedia Cat: S007) stains for histological staining, LDH Cytotoxicity Assay Kit (BioVision, Cat: K311-400), acridine orange (AO; Cat: A6014), propidium iodide (Cat: P4864), and all quantitative reverse transcription (qRT)-polymerase chain reaction (PCR) primers were purchased from Sigma-Aldrich. Fetal bovine serum (FBS; Gibco, Cat: 10270), Dulbecco's modified Eagle's medium (DMEM; Cat: SH30243.01), Antibiotic Antimycotic Solution (Cat: A002), Trypsin-EDTA (Himedia Labs, Cat: TCL007), mortar, pestle, and micropestle for grinding tissues were purchased from local vendors.
Prostate tissue collection and ethics
Prostate tissues samples (normal and prostatic adenocarcinoma) were collected from study participants in the Department of Urology, Velammal Medical College Hospital & Research Institute (VMCH & RI), Madurai, India, as per the Indian Council of Medical Research guidelines. The study was approved by the Institute Ethical Board of VMCH & RI for the identification, collection, and characterization of prostate samples. Both oral and written consent were obtained from the patients after a detailed briefing about the study. Trained surgical physician assistants at the hospital were involved in the sample collection procedure. Samples were then transported in frozen state using liquid nitrogen containers to the Department of Genetic Engineering, Madurai Kamaraj University, where the subsequent tissue processing were carried out. The study at Madurai Kamaraj University was approved by the Institutional Ethical Committee. Samples were authenticated and well characterized by physicians at the Department of Pathology, VMCH & RI, and grading of prostate tissues was done using Gleason scoring system.
Hematoxylineeosin staining of prostate tissues
Prostate samples included in the study were obtained under the guidance of transrectal ultrasonography. Immediately after surgery, a portion of the prostate tissue was cryo-freezed using liquid nitrogen. The other portion was fixed in 10% neutral buffered formalin, processed, and embedded in a paraffin block. A 4-mmthick section was taken from these blocks in microslides, and routine hematoxylin and eosin (H&E) staining was performed. Histopathological examination was carried out on samples from patients with prostate adenocarcinoma and patients with nonmalignant prostate lesions. In tumor cases, in addition to the histological type of the tumor, tumor grading (Gleason scoring system), status of perineural invasion, and in situ components were noted and documented in the report. Necessary images were also taken using a light microscope with an inbuilt camera (Coslab HL-23).
Collection and preparation of W. somnifera root extract
Roots of W. somnifera were collected from an ayurvedic medicinal farm (Madurai, Tamilnadu, India) identified by a botanist, and a voucher specimen was kept for future studies. The roots were rendered free from all impurities by washing with distilled water and shade-dried. Dried roots were grinded into powder and used (about 50 g) for each extraction with analytical-grade methanol (500 mL) in a Soxhlet apparatus as previously described. 23 The extraction process was carried out for 24 hours, and the extract was concentrated using a rotary vacuum evaporator at 55 C. Concentrated crude extract was stored at e80 C. A portion of the concentrated extract was weighed and reconstituted in serum-free medium compatible for cell culture studies. The extract was filtered using 0.2-mm sterile syringe filters to avoid contamination.
Cell culture
The androgen-independent and highly metastatic human prostate cancer cell line (PC3) was purchased from the National Centre for Cell Sciences, Pune, India. As these cells were characterized as androgen receptor negative (ATCC No. HB8065), cells were grown in DMEM without any androgen supplements and were cultured with 10% FBS and 1Â antibiotic antimycotic solution (containing penicillin, streptomycin, and amphotericin B). The cultures were maintained at 37 C, 5% CO 2 and subcultured periodically using 0.25% trypsineEDTA solution.
MTT assay
The MTT assay is a simple nonradioactive colorimetric assay used to directly measure cell proliferation or viability and indirectly cell toxicity. The MTT assay relies on the mitochondrial activity of cells, and thus serves as a biomarker of cell metabolism. To determine cell viability, the PC3 cells were seeded at a density of 1 Â 10 4 cells/well in a 96-well plate at 37 C in 5% CO 2 . At 75e80% confluency, cells were treated with W. somnifera extract in varying concentrations and the well without W. somnifera extract acts as control. After 24 hours of treatment, media containing plant extracts were removed and 100 mL fresh medium was added along with 10 mL MTT dye solution (5 mg/mL in phosphate buffer pH 7.4).
After 4 hours of incubation at 37 C in 5% CO 2 , the medium was removed and the formazan crystals were solubilized with 200 mL dimethyl sulfoxate. The absorbance of each well was read on a microplate reader at 575 nm. The relative cell viability (%) related to control wells containing cell culture medium without W. somnifera extract was calculated as [A] test /[A] control Â 100.
Lactate dehydrogenase assay
Lactate dehydrogenase (LDH) is an oxidoreductase enzyme present in almost all organisms. Cells release LDH into the blood circulation (in vivo) or into culture supernatant (in vitro settings) when exposed themselves to any injurious stimuli or undergoing cell death. In this colorimetric LDH quantification assay, LDH reduces Nicotinamide Adenine Dinucleotide (Oxidized form) to Nicotinamide Adenine Dinucleotide-Hydrogen (Reduced form), which then interacts with a specific probe to produce a color that can be read at l max ¼ 450 nm.
Cell morphology assessment using phase contrast imaging
PC3 cells were seeded at 4 Â 10 5 cells/well in six-well plates.
Cells were treated with and without W. somnifera extracts at various concentrations for 24 hours at 37 C in 5% CO 2 . The control well contains cell culture medium without W. somnifera extract. At the end of 24 hours, the cells were rinsed thrice with phosphatebuffered saline (pH 7.4), and images were taken by inverted phase contrast microscope (TS 100; Nikon, Tokyo, Japan) with 10Â magnification.
AO staining
To assess the occurrence of acidic vesicular organelles promoted by cytoplasmic proteins and lytic components, PC3 cells were treated with W. somnifera extracts for 24 hours and cells were stained with AO. Briefly, cells were incubated with AO (1 mg/mL) for 10 minutes then examined under a fluorescent microscope (Nikon, Japan) with 10Â magnification.
Cell cycle analysis
Cells were seeded in a 35-mm plate at a density of 5 Â 10 5 cells/ plate, and cells were treated with 10 mg/mL of W. somnifera extract for 24 hours. Cells without treatment are taken as control. After 24 hours, cultured cells were collected in 1 mL extraction buffer (45mM Na 2 HPO 4 , 2.5mM citric acid, 0.1% Triton X-100, 1 mg/mL RNase, and 50 mg/mL propidium iodide, pH ¼ 7.8), and analyzed using BD FACSAria III and the data were analyzed using Flow Jo software.
Quantitative real-time PCR studies
Quantitative RT-PCR was performed in an ABI 7500 sequence detection system (Applied Biosystems) using SyBr Green probe. Total RNA was isolated using TRI reagent. RT was performed with 1 mg DNAse treated RNA for 3 hours at 37 C. The expression levels of interleukin-8 (IL-8) and cyclooxygenase-2 (COX-2) were quantified against an internal control, b-actin. Relative transcript levels were determined according to the manufacturer's protocol by calculating the 2^(eddcT) values.
Statistical analysis
We used KolmogoroveSmirnov's test to determine the normality of distribution. All clinical data were expressed as mean ± standard deviation. Comparisons between the two groups were performed using unpaired parametric Student t test or one-way analysis of variance, followed by Tukey's multiple comparison post hoc test. Statistical significance was accepted if the null hypothesis was rejected at p 0.05. Data analyses were performed using Windows-based GraphPad PRISM (GraphPad Software, Inc., San Diego, CA, USA).
Results
Characteristics of study participants and samples
The study population comprised elderly male individuals with and without prostate cancer in the age group between 60 and 75 years. Prostate tissues were obtained from patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia or transrectal biopsy for diagnosis of prostate cancer and transrectal ultrasonography channeling for metastatic prostate cancer at VMCH & RI. Based on the morphometric assessments (prostate size, weight) and urine flow pattern, individuals were sorted as patients with nonneoplastic [normal prostate (NP)] diseases and patients with prostate cancer (PC). In both groups, only those patients without tobacco smoking and alcohol drinking habits were considered for the study. Based on histological grading (Fig. 1) and Gleason scoring, PC individuals (prostatic adenocarcinoma) were identified, fixed for surgical procedures. A detailed questionnaire and an informed consent were obtained from all study participants prior to surgical procedures. Samples were collected with an utmost interest to confirm the expression levels of metastatic markers, and cell cycle associated "cyclins" are the same in both prostate tissues and PC cell line (PC3).
Assessment of isolated total RNA
Total RNA was isolated from prostate tissue and PC3 cells ( Fig. 2A, 2B ) using TRI reagent. Integrity and purity of isolated RNA samples after DNase I treatment was quantified using nanodrop spectrophotometer and running 1% formaldehydeeagarose gel (Fig. 2C, 2D ).
W. somnifera extract exhibits reduced viability and increased cytotoxicity in PC3 cells
Cell viability and cytotoxicity of W. somnifera extract at different concentrations (10 mg/mL, 25 mg/mL, 50 mg/mL, 100 mg/mL, 200 mg/ mL) was carried out in PC3 cell line at 24 hours, to determine the IC 50 (50% growth inhibition) value using MTT assay. The percentage cell viability of PC3 cells significantly decreased (from 40% to 20%) with increasing concentrations of W. somnifera extract as shown (Fig. 3A) . The half-minimal cytotoxicity (IC 50 value) in PC3 cells was found at the 10 mg/mL concentration of W. somnifera with more than 40% decrease in viable cells. Staining of PC3 cells with trypan blue dye further indicated that W. somnifera extract induces uptake of trypan blue, suggesting cellular death (not shown). Interestingly, the percentage cytotoxicity of PC3 cells significantly increased (from 10% to 48%) with increasing concentrations (10 mg/mL, 25 mg/ mL, 50 mg/mL, 100 mg/mL, 200 mg/mL) of W. somnifera extract quantified in cell culture supernatant using LDH cytotoxicity assay (Fig. 3B) . Hence, it was evident that W. somnifera extract exhibits antiproliferative potential in androgen-independent prostate cancer cell line (PC3).
Assessment associated with cellular morphology in PC3 cells
To check whether W. somnifera treatments induced alteration in the morphology of PC3 cells at various concentrations, we carried out imaging under a phase contrast microscope (Nikon Eclipse TS100) after 24 hours. The cell morphology of W. somnifera-treated cells was found to be irregular and stretched out. Furthermore, the nucleus was enlarged with fine fenestrations in the cell membrane. All images were taken in 10Â magnification. As concentration of W. somnifera increases, confluency of cells decreases with shrinkages as shown (Fig. 4A) . Staining of PC3 cells with AO dye further indicated that W. somnifera extract at 10 mg/mL is able to demonstrate that cells are not intact as seen in control cells without treatment (Fig. 4B) .
Cell cycle analysis
We analyzed the effect of W. somnifera extract on cell cycle progression. Overnight serum starvation was done to achieve 80% synchronization of cells in G 0 /G 1 phase. PC3 cells were then treated with 10 mg/mL W. somnifera, and cells without treatment acting as control were analyzed 24 hours after treatment using propidium iodide labeling (Fig. 5A) . The percentage of PC3 cells decreased from 63% to 3% in G 0 /G 1 phase, increased from 3% to 6% in S phase, and significantly increased from 30% to 56% in G 2 /M phase (P ¼ 0.044). The accumulation of cells was found to be greater in G 2 /M phase, suggesting a cell cycle arrest at G 2 /M phase. Such arrest at G 2 /M phase indicates inhibition of cell proliferation by the extract in PC3 cells (Fig. 5B ).
W. somnifera extract inhibits the expression of IL-8 and COX-2 in PC3 cells
We quantified the real-time expression of metastatic markers, IL-8 and COX-2, in prostate cancer cells (PC3) with and without W. somnifera extract treatment in a 5% CO 2 incubator for 24 hours. To also compare the expression pattern of these markers in tissues, we have processed in parallel the prostate tissue samples obtained from study participants (NP and PC, n ¼ 3 in each group). The primers used in this study for qRT-PCR analysis are given in Table 1 . We observed a significant increase in the percentage fold expression of IL-8 (P ¼ 0.032) and COX-2 (P ¼ 0.038) in prostatic adenocarcinoma (PC) tissues compared with the normal prostate (NP; Fig. 6A) . Similarly, the expression levels of IL-8 and COX-2 were observed to be as high as 80% and 100%, respectively, in prostate cancer cells (PC3) without any W. somnifera extract treatment. After 24 hours of treatment with 10 mg/mL W. somnifera extract, PC3 cells showed a significant decrease in the expression levels of IL-8 (P ¼ 0.028) and COX-2 (P ¼ 0.005; Fig. 6B ). 
W somnifera extract attenuates the expression of cell cycle checkpoints in PC3 cells
We proceeded to determine the expression levels of the cell checkpoint markers, especially cyclins A2, B1, and D1, in both PC3 cells and in prostate tissue samples using quantitative RT-PCR. The expression of cyclin D1 (P ¼ 0.026) was found to be significantly decreased, whereas cyclin A2 (P ¼ 0.153) and B1 (P ¼ 0.115) levels were found to be attenuated. We compared the expression pattern of cyclins A2 and D1 using qRT-PCR (Fig. 6C) and that of cyclin B1 by the semiquantitative RT-PCR method (Fig. 6F ) using PC3 cells and prostate tissues, respectively, to better understand the inhibitory effects of W. somnifera extract over cell cycle regulation.
Discussion
Prostatic adenocarcinoma is a highly metastatic, nonandrogenic, noncutaneous malignancy in men. 1, 24 At this stage, the disease is incurable and causes significant mortality. Currently available therapeutic and disease management strategies such as hormonal therapy, radiotherapy, chemotherapy, and clinical surgery are successful to some extent in the prevention and control of prostatic tumorigenesis and metastasis. 25 Determination of appropriate treatment regime is purely based on patient's age, disease status, compatibility to chemotherapeutics, and tolerance to androgen deprivation. Therefore, patients are in need of alternative and efficient treatment strategies that can combat the motility of cancer cells, thereby preventing the disease progression and prolonging the survival rate.
Epidemiological studies pertaining to the therapeutics of dietary agents have shown that consumption of naturally available fruits, vegetables, and spices lowers the incidence of cancers. 26 Dietary agents are found to possess many biologically active compounds that are ubiquitous in plants. W. somnifera, an Indian ayurvedic medicinal plant, has been traditionally used for the treatment of cancers, as well as inflammatory and neurological disorders. 8e13 In the present study, we investigated the effect of W. somnifera root extract on proliferation, metastasis, and cell cycle transition in androgen-independent prostate cancer cells (PC3) through the expression of IL-8 and COX-2 in comparison with prostatic adenocarcinoma tissues.
To address the first and foremost questiondwhether the isolated prostate derived tissues and the prostate cancer cells have similar malignant featuresdwe carried out a detailed microscopic and histological evaluation. Prostate tissues and prostate cells were well characterized based on H&E staining and AO staining, respectively. Consequently, we assessed the proliferative potential of PC3 cells in in vitro androgen-deprived culture condition in response to the administration of W. somnifera extract at 24 hours. It was evident that cells without treatment grow to a maximum extent with no compromise in viability, whereas cells with varying concentrations of W. somnifera grow with reduced viability. This is further confirmed by the trypan blue exclusion assay, where viable (intact) cells exclude the uptake of dye in contrast to the nonviable cells. Further calorimetric analysis of the cell culture supernatants (spent medium) reveals that W. somnifera extract possess cytotoxic properties, which were quantified by the levels of LDH released by PC3 cells. Cells without any treatment do not show the release of LDH, whereas cells treated with various concentrations of W. somnifera released significant amounts of LDHdthus confirming that W. somnifera extract exhibits antiproliferative potential in androgen-independent prostate cancer cells.
IL-8 and COX-2 were considered to be the key player in the regulation of metastasis and angiogenesis in prostate cancer. 21, 22 Inflamed neoplastic cells secrete excess IL-8, which enhances the growth and tumorigenicity in human prostate cancer mediated by the induction of MMP-9 expression.
27e34 When compared with normal tissues, malignant tissues were found to induce COX-2 expression constitutively; this remains throughout the process from dysplasia to metastasis. This adaptation further favors tumor progression, contributes in cellular adhesion to the extracellular matrix, and makes cells resistant to apoptosis. 22 In the current study, we examined the expression of IL-8 and COX-2 levels in both prostate tissues and in PC3 cells by qRT-PCR analysis. Our results, both in prostate tissues and in PC3 cell lines, showed an increased Based on our results, we believed that W. somnifera-induced selective inhibitory potential against androgen-independent prostate cancer was achieved by attenuating proliferative, metastatic and angiogenic signals mediated by IL-8 and COX-2 expression and by arresting cell cycle in G 2 /M phase (Fig. 7) . These results were reliable and consistent with previous reports. Seaton et al 30 have
shown that IL-8 signals promote the androgen-independent proliferation of prostate cancer cells by inducing the expression and activation of androgen receptors. Richardsen et al 33 have shown that in cancerous prostatic tissues due to insensitivity and adaptability to the apoptotic signals, the expression of COX-2 was enhanced. 33 In general, activation of cell cycle checkpoints play a major role in maintaining genomic stability. Consequently, W. somnifera blocks the cell cycle transition in G 2 /M phase and thereby prevents the entry of cells into mitotic phase and leads to DNA damage and cell death. It is known that the key player involved in G 2 to M phase transition is cyclin B1. Notably, W. somnifera downregulates the expression of cyclins A2, B1, and D1. Moreover, it should be noted that the expression of p53 is crucial for cell death in cancerous tissues; however, PC3 cells do not express p53. 36 Hence, our results indicate that W. somnifera induces irreversible G 2 /M arrest in a p53-independent manner, which was associated with the initiation of mitotic catastrophe (delayed mitosis linked cell death) in androgen-independent prostate cancerous cells. 37, 38 This study opens up new avenues and lays a platform for future clinical investigation and therapeutic modalities for the prevention and treatment of prostate cancer. In conclusion, our results suggest that regular intake of W. somnifera (a good dietary agent) may prolong life expectancy in prostatic adenocarcinoma patients along with the prescribed drug of choice.
Limitations
There are several limitations in the current study. Because of the small sample size, we could not perform correlation analysis between the observed Gleason scores with the hematological parameters. Certain clinical observations and malignant features did not attain statistically significant level. The prostate tissues collected in the study were used to compare the expression status of the key markers in prostate cancer cell line (PC3) only at the mRNA level.
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